Breaking News

Tweet TWEET

Galapagos NV : NYSE Liffe lists Equity Options on Galapagos

         Galapagos NV : NYSE Liffe lists Equity Options on Galapagos

Brussels and  Mechelen,  Belgium,  30  April 2013  -  Today  NYSE  Liffe,  the 
Europe-based derivatives business of NYSE Euronext (NYX), added options on the
shares of Galapagos (Euronext: GLPG), a clinical stage biotech company focused
on developing novel medicines, to its highly successful range of equity option
classes. The options are available on the Brussels derivatives market of NYSE
Liffe under the ticker GLS.

Vincent Van Dessel, CEO of NYSE  Euronext Brussels commented: "We are  pleased 
to announce the listing of options on Galapagos, a successful Belgian  company 
and a great example of our leading  role in the biotech industry niche.  This 
listing will further enhance the visibility of the company."

Ade Cordell, Executive  Director, Head  of Equity Derivatives  added: "We  are 
delighted with the listing  of this new option  class on our Brussels  market. 
With the addition of the Galapagos option class to our existing central order
book contracts, we are offering  our market participants a highly  diversified 
set of liquid derivatives for their investment needs.

Onno van de Stolpe, CEO of  Galapagos, commented: "Listing of ordinary  shares 
on NYSE Euronext has played an important role in the growth of Galapagos since
the IPO in 2005. The listing of options on the shares of our company marks  a 
further step in  the company's development.  We believe that  this may  offer 
shareholders an alternative  financial instrument  on the  NYSE Liffe  market, 
enhance the liquidity of our share,  and increase the visibility of  Galapagos 
in the financial markets."

These American-style options  will expire on  the third Friday  of the  expiry 
month and will  have initial lifetimes  of one to  twelve months. Options  on 
Galapagos are introduced under trading symbol GLS.

Each option represents 100 shares in  Galapagos and will be centrally  cleared 
via LCH.Clearnet  SA. Liquidity  in  the options  will  be supported  by  All 
Options International B.V..  NYSE Liffe  lists stock options  (also known  as 
individual equity options) on more than 200 leading European companies via the
Amsterdam, Brussels, London and Paris central order books.

The introduction of the new option class  on Galapagos is the second one on  a 
Belgian biotech company.  Galapagos is specialized  in novel  modes-of-action 
medicines, with a large pipeline of four clinical, seven pre-clinical, and  30 
discovery  small-molecule   and   antibody  programs   in   cystic   fibrosis, 
inflammation, antibiotics,  metabolic  disease, and  other  indications.  The 
Galapagos Group,  including fee-for-service  companies BioFocus,  Argenta  and 
Fidelta, has around 800 employees  and operates facilities in five  countries, 
with global headquarters in Mechelen, Belgium.

To mark today's special occasion, Onno  van de Stolpe, CEO of Galapagos,  rang 
the opening bell which denotes the opening of NYSE Euronext's European market,
together with Vincent Van Dessel, CEO of NYSE Euronext Brussels.

About NYSE Euronext
NYSE Euronext (NYX)  is a  leading global  operator of  financial markets  and 
provider of  innovative  trading  technologies. The  company's  exchanges  in 
Europe and the  United States trade  equities, futures, options,  fixed-income 
and  exchange-traded  products.  With   approximately  8,000  listed   issues 
(excluding European Structured Products),  NYSE Euronext's equities markets  - 
the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and  NYSE 
Arca - represent one-third of the world's equities trading, the most liquidity
of any global exchange group. NYSE Euronext also operates NYSE Liffe, one  of 
the leading  European derivatives  businesses and  the world's  second-largest 
derivatives business by  value of trading.  The company offers  comprehensive 
commercial technology,  connectivity and  market  data products  and  services 
through NYSE Technologies. NYSE Euronext is  in the S&P 500 index. For  more 
information, please visit: http://www.nyx.com.

About Galapagos
Galapagos   (Euronext:   GLPG;   OTC:   GLPYY)   is   specialized   in   novel 
modes-of-action, with a large pipeline  of four clinical, seven  pre-clinical, 
and 30  discovery small-molecule  and antibody  programs in  cystic  fibrosis, 
inflammation, antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, about  to 
enter Phase  2b studies.  AbbVie  and Galapagos  signed a  worldwide  license 
agreement whereby  AbbVie  will be  responsible  for further  development  and 
commercialization after  Phase  2b.  Galapagos  has  another  selective  JAK1 
inhibitor in Phase 2  in lupus and  psoriasis, GSK2586184 (formerly  GLPG0778, 
in-licensed by  GlaxoSmithKline  in  2012).  GLPG0187  is  a  novel  integrin 
receptor antagonist  currently in  a Phase  1b patient  study in  metastasis. 
GLPG0974 is the  first inhibitor of  FFA2 to be  evaluated clinically for  the 
treatment of IBD;  this program is  currently in  a Proof of  Concept Phase  2 
study, with results expected early 2014.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has around 800 employees  and operates facilities in five  countries, 
with global  headquarters  in  Mechelen,  Belgium.  Further  information  at: 
www.glpg.com

CONTACT
NYSE Euronext
Jean-Yves Daxhelet
Tel.: +32 (0)2 213 13 03
E-mail: jean-yves.daxhelet@interelgroup.com

Galapagos
Elizabeth Goodwin, Director Investor Relations
Tel.: +31 6 2291 6240
E-mail: ir@glpg.com

This  release  may  contain  forward-looking  statements,  including,  without 
limitation,  statements  containing   the  words  "believes,"   "anticipates," 
"expects," "intends," "plans," "seeks,"  "estimates," "may," "will,"  "could," 
"stands  to,"  and   "continues,"  as  well   as  similar  expressions.   Such 
forward-looking statements may involve known and unknown risks,  uncertainties 
and other factors which might  cause the actual results, financial  condition, 
performance  or  achievements  of  Galapagos,  or  industry  results,  to   be 
materially  different  from   any  historic  or   future  results,   financial 
conditions,  performance  or  achievements   expressed  or  implied  by   such 
forward-looking statements. Given these  uncertainties, the reader is  advised 
not to  place any  undue reliance  on such  forward-looking statements.  These 
forward-looking statements speak only  as of the date  of publication of  this 
document. Galapagos  expressly disclaims  any obligation  to update  any  such 
forward-looking statements  in this  document  to reflect  any change  in  its 
expectations with  regard  thereto or  any  change in  events,  conditions  or 
circumstances on which any such statement is based, unless required by law  or 
regulation.

NYSE Liffe lists Equity Options on Galapagos

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Galapagos NV via Thomson Reuters ONE
HUG#1697598
 
Press spacebar to pause and continue. Press esc to stop.